Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 224   

Articles published

SNY 49.97 +1.17 (2.40%)
price chart
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Top Stories: Papa Murphy's Holdings, Inc. (NASDAQ:FRSH), Vince Holding ...  Stock Transcript
Bristol-Myers Squibb Co, Sanofi SA (ADR), and Novartis AG (ADR) Lead 2015 ...
Bristol-Myers Squibb Co (NYSE:BMY), Sanofi SA (ADR)(NYSE:SNY), and Novartis AG's (ADR)(NYSE:NVS) will be 2015's most valuable new drug launches, says a report published on Monday.
New Blockbuster Drugs Expected From Sanofi SA (ADR) (NYSE:SNY), Bristol ...  NYSE Post
Sanofi SA (ADR), Evotec Enter Into �250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth �250 million.
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Sanofi SA (ADR) Reports Positive Cardiovascular Safety Results For Diabetes ...
Sanofi SA (ADR) (NYSE:SNY) announced Thursday positive results for its diabetes drug Lyxumia from a Phase III study evaluating the cardiovascular risks of the said drug.
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin  Bidness ETC
Sanofi SA (ADR) (NYSE:SNY) can sell Lantus: approved by US  Investor Wired
Sanofi SA (ADR) New CEO To Focus On US Market
Sanofi's quest to find a replacement for ousted CEO Chris Viehbacher has come to an end. It finally announced Thursday the appointment of Olivier Brandicourt, head of Bayer AG's (ADR)(OTCMKTS:BAYRY) healthcare business, as its new CEO.
Sanofi Appoints Olivier Brandicourt CEO -- 3rd Update  Nasdaq
GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR ...
Home > GlaxoSmithKline plc (ADR), Merck & Co., Inc., Pfizer Inc., Sanofi SA (ADR): Are Big Pharma Stocks In Trouble?
Sanofi SA (ADR): Differing Regulatory Decisions Harm Global Drug Research
The marked difference in the timings of regulatory decisions worldwide regarding new medicines is a pressing issue affecting the profitability of pharmaceutical research, as discussed by Elias Zerhouni, head of research at Sanofi SA (ADR) (NYSE:SNY) on ...
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (NYSE:SNY) has launched its inhalable insulin Afrezza in the US, the company announced before the US markets opened for trading Tuesday.
Sanofi, Mannkind Put Inhaled Insulin Afrezza on US Market  Nasdaq